The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Neuromodulation in epilepsy: state-of-the-art approved therapies
Abstract
Three neuromodulation therapies have been appropriately tested and approved in refractory focal epilepsies: vagus nerve stimulation (VNS), deep brain stimulation of the anterior nucleus of the thalamus (ANT-DBS), and closed-loop responsive neurostimulation of the epileptogenic zone or zones. These therapies are primarily palliative. Only a few individuals have achieved complete freedom from seizures for more than 12 months with these therapies, whereas more than half have benefited from long-term reduction in seizure frequency of more than 50%. Implantation-related adverse events primarily include infection and pain at the implant site. Intracranial haemorrhage is a frequent adverse event for ANT-DBS and responsive neurostimulation. Other stimulation-specific side-effects are observed with VNS and ANT-DBS. Biomarkers to predict response to neuromodulation therapies are not available, and high-level evidence to aid decision making about when and for whom these therapies should be preferred over other antiepileptic treatments is scant. Future studies are thus needed to address these shortfalls in knowledge, approve other forms of neuromodulation, and develop personalised closed-loop therapies with embedded machine learning. Until then, neuromodulation could be considered for individuals with intractable seizures, ideally after the possibility of curative surgical treatment has been carefully assessed and ruled out or judged less appropriate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kwan, P., Arzimanoglou, A., Berg, A. T., Brodie, M. J., Allen Hauser, W., Mathern, G., Moshé, S. L., Perucca, E., Wiebe, S., & French, J. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2009.02397.x · Cited by 4,877
Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy
Fisher, R., Salanova, V., Witt, T., Worth, R., Henry, T., Gross, R., Oommen, K., Osorio, I., Nazzaro, J., Labar, D., et al. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2010.02536.x · Cited by 1,918
Chen, Z., Brodie, M. J., Liew, D., & Kwan, P. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.3949 · Cited by 1,514
Responsive cortical stimulation for the treatment of medically intractable partial epilepsy
Morrell, M. J. (2011) · Neurology · doi:10.1212/wnl.0b013e3182302056 · Cited by 1,282
Vagus nerve stimulation therapy for partial-onset seizures: A randomized active-control trial
Handforth, A., DeGiorgio, C. M., Schachter, S. C., Uthman, B. M., Naritoku, D. K., Tecoma, E. S., Henry, T. R., Collins, S. D., Vaughn, B. V., Gilmartin, R. C., et al. (1998) · Neurology · doi:10.1212/wnl.51.1.48 · Cited by 1,107
Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy
Salanova, V., Witt, T., Worth, R., Henry, T. R., Gross, R. E., Nazzaro, J. M., Labar, D., Sperling, M. R., Sharan, A., Sandok, E., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001334 · Cited by 821
Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy
Morris, G. L., Mueller, W. M., & The Vagus Nerve Stimulation Study Group E–E (1999) · Neurology · doi:10.1212/wnl.53.8.1731 · Cited by 724
Adverse effects of antiepileptic drugs
Perucca, P., & Gilliam, F. G. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70153-9 · Cited by 694
Heck, C. N., King‐Stephens, D., Massey, A. D., Nair, D. R., Jobst, B. C., Barkley, G. L., Salanova, V., Cole, A. J., Smith, M. C., Gwinn, R. P., et al. (2014) · Epilepsia · doi:10.1111/epi.12534 · Cited by 651
Self-citation
Cited by
Perucca, E., Perucca, P., White, H. S., & Wirrell, E. C. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00151-5 · Cited by 305
Asadi-Pooya, A. A., Brigo, F., Lattanzi, S., & Blumcke, I. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01048-6 · Cited by 265
Metadata
- Authors
- Ryvlin, P., Rheims, S., Hirsch, L. J., Sokolov, A., & Jehi, L.
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2021-12
- Volume
- 20
- Issue
- 12
- Pages
- 1038-1047
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W3208234271
- Cited by
- 314
- References
- 82
- FWCI
- 26.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuromodulation in epilepsy: state-of-the-art approved therapies. https://app.cochat.ai/papers/10.1016/s1474-4422(21)00300-8
- The paper
- Ryvlin, P., Rheims, S., Hirsch, L. J., Sokolov, A., & Jehi, L. (2021). Neuromodulation in epilepsy: state-of-the-art approved therapies. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(21)00300-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.